THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Sanofi makes Genzyme bid hostile

French firm trying to draw drug maker to table, analysts say

Sanofi Aventis chief executive Chris Viehbacher has met with many of Genzyme’s biggest investors. Sanofi Aventis chief executive Chris Viehbacher has met with many of Genzyme’s biggest investors. (John Tlumacki/ Globe Staff File/ 2009)
By Robert Weisman and Erin Ailworth
Globe Staff / October 5, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Frustrated by a lack of cooperation from executives at Genzyme Corp. , French drug maker Sanofi Aventis SA yesterday began a hostile bid for the state’s largest biotechnology firm. (Full article: 961 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass